EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High‐Throughput 3D Glioblastoma Model in Glycosaminoglycan Hydrogels for Personalized Therapeutic Screening

Rajvinder Kaur Trautmann iD, Nicholas Dennison, Kathleen McCortney, Solveig Klier, Mehmet Ilyas Cosacak, Carsten Werner, Goktug Akyoldas, Craig M Horbinski, Uwe Freudenberg, Caghan Kizil

Macromolecular Bioscience · 2026

DOI: 10.1002/mabi.202500394 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Macromolecular Bioscience, 2026. Verfasst von Rajvinder Kaur Trautmann und 9 weiteren Autor:innen. Beteiligte Einrichtung: Neuron-D GmbH, Dresden, Germany. Hauptthemen laut MEDLINE: Glioblastoma, Hydrogels, Glycosaminoglycans, Precision Medicine. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, European Union Regional Development Fund (EFRE) and Sachsische Aufbaubank (SAB).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is a devastating brain tumor with limited treatment success, partly because in vitro models poorly mimic in vivo complexity. This study introduces a high‐throughput 3D culture platform utilizing modular starPEG–glycosaminoglycan (GAG) hydrogels that enable independent control of extracellular matrix (ECM) cues: stiffness, cytokine affinity, matrix metalloproteinase‐responsive remodeling, and cell adhesiveness via integrin‐binding RGD peptides. This platform supports encapsulation of patient‐derived GBM cells, recreates physiologically relevant tumor microenvironments in 384‐well plates, and enables automated drug testing on primary cells. Transcriptomic analyses show that 3D cultures recapitulate primary and recurrent GBM programs‐ including hypoxia‐, immune‐, and ECM‐regulatory pathways driving growth, invasion, and resistance, without externally imposed hypoxia. The platform's versatility extends to drug screening, where single and combinatorial treatments produce reproducible cytoskeletal and transcriptomic responses. Notably, the system revealed dose‐dependent reductions in invasive filaments and spheroid architecture with 5‐fluorouracil/uridine and carmustine, demonstrating its potential for optimizing combinatorial therapies. This 3D model surpasses 2D cultures, capturing tumor‐specific molecular programs and offering a robust tool for translational research. Despite lacking vascular or immune components, its tunability, scalability, and clinical relevance make it a strong basis for advanced co‐cultures. By delivering reliable, individualized therapeutic data within a short timeframe, this model holds transformative potential for personalized GBM treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaHydrogelsGlycosaminoglycansPrecision MedicineHigh-Throughput Screening AssaysBrain NeoplasmsCell Culture Techniques, Three DimensionalHumansCell Line, TumorExtracellular MatrixTumor Microenvironment

Stichwörter der Autor:innen

Glioblastomabioengineered tumor microenvironmenthigh‐throughput screeningpatient‐derived cellspersonalized medicinestarPEG‐heparin hydrogel

Substanzen

HydrogelsGlycosaminoglycans

Autor:innen und Institutionen

  • Neuron-D GmbH, Dresden, Germany.
  • Leibniz Institute of Polymer Research Dresden (IPF), Dresden, Germany.
  • Nervous System Tumor Bank, Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • German Center for Neurodegenerative Diseases (DZNE), Dresden, Germany.
  • Koc University Hospital, İstanbul, Türkiye.
  • Departments of Pathology and Neurosurgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.

ORCID-Profile: Rajvinder Kaur Trautmann

Förderung

  • NCI NIH HHS
  • European Union Regional Development Fund (EFRE) and Sachsische Aufbaubank (SAB)

Zitieren

APA

Trautmann, R. K., Dennison, N., McCortney, K., Klier, S., Cosacak, M. I., Werner, C., Akyoldas, G., Horbinski, C. M., Freudenberg, U., & Kizil, C. (2026). High‐Throughput 3D Glioblastoma Model in Glycosaminoglycan Hydrogels for Personalized Therapeutic Screening. Macromolecular Bioscience. https://doi.org/10.1002/mabi.202500394

Vancouver

Trautmann RK, Dennison N, McCortney K, Klier S, Cosacak MI, Werner C, et al. High‐Throughput 3D Glioblastoma Model in Glycosaminoglycan Hydrogels for Personalized Therapeutic Screening. Macromolecular Bioscience. 2026. doi:10.1002/mabi.202500394

BibTeX
@article{Trautmann2026,
  author = {Trautmann, Rajvinder Kaur and Dennison, Nicholas and McCortney, Kathleen and Klier, Solveig and Cosacak, Mehmet Ilyas and Werner, Carsten and Akyoldas, Goktug and Horbinski, Craig M and Freudenberg, Uwe and Kizil, Caghan},
  title = {High‐Throughput 3D Glioblastoma Model in Glycosaminoglycan Hydrogels for Personalized Therapeutic Screening},
  journal = {Macromolecular Bioscience},
  year = {2026},
  doi = {10.1002/mabi.202500394}
}
Kostenlos starten →